Overview

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Status:
Recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy

Phase:

Phase 3

Details

Lead Sponsor:

Rakuten Aspyrian, Inc.
Rakuten Medical, Inc.

Treatments:

Cetuximab
Docetaxel
Methotrexate